Abstracts Archive - Page 2406 of 2605 - ACR Meeting Abstracts

Abstract Number: 344 • 2013 ACR/ARHP Annual Meeting
Clinical Phenotype Of Patients With Arthritis Mutilans Has Important Differences Compared To Other Patients With Psoriatic Arthritis
Muhammad Haroon¹, Phil Gallagher² and Oliver FitzGerald¹, ¹Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Rheumatology, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Arthritis mutilans (AM), a severe form of psoriatic arthritis (PsA), is characterised clinically by digital shortening resulting from osteolysis and/or erosions. It is still…
Abstract Number: 345 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Peri-Articular Manifestations (Enthesitis and Dactylitis) and Disease Activity In Psoriatic Arthritis Patients: Impact Of Treatment With TNF Inhibitors In a Real-World Canadian Population
Proton Rahman¹, Denis Choquette², William G. Bensen³, Majed M. Khraishi⁴, Isabelle Fortin⁵, Andrew Chow⁶, Maqbool K. Sheriff⁷, Julie Vaillancourt⁸, John S. Sampalis⁸, Susan M. Otawa⁹, Allen J. Lehman⁹ and May Shawi¹⁰, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ³Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁴Nexus Clinical Research, St John's, NF, Canada, ⁵Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁶University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁰Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: To determine the point prevalence of peri-articular manifestations (PAMs) in psoriatic arthritis (PsA) patients treated with anti-TNF in a real-world, Canadian, routine clinical practice…
Abstract Number: 346 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis, a More Severe Disease Than Psoriatic Arthritis? A Comparison Of Disease Activity In Patients With Psoriatic Arthritis and Rheumatoid Arthritis From The Swedish Early Psoriatic Arthritis Registry (SwePsA) and The Swedish Rheumatology Registry For Early RA (SRR)
Gerd-Marie Alenius¹, Tomas Husmark², Elke Theander³, Per Larsson⁴, Mats Geijer⁵, Annika Teleman⁶ and Ulla R. C. Lindqvist⁷, ¹Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ²Department of Rheumatology, Falu Hospital, Falun, Sweden, ³Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Dept of Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ⁵Skåne University Hospital, Lund, Center for Medical Imaging and Physiology, Lund, Sweden, ⁶Department of Rheumatology, Spenshult Hospital, Oskarstrom, Sweden, ⁷Department of Medical Sciences, Rheumatology, University Hospital, Uppsala university, Uppsala, Sweden
Background/Purpose: In clinical practise patients with psoriatic arthritis (PsA) seem to have milder disease expression compared with patients having rheumatoid arthritis (RA). Studies have, however,…
Abstract Number: 347 • 2013 ACR/ARHP Annual Meeting
Factors Explaining The Discrepancy Between Patient and Physician Global Assessment Of Disease Activity In Psoriatic Arthritis
Lihi Eder¹, Arane Thavaneswaran¹, Vinod Chandran², Richard J. Cook³ and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: Patients and physicians often perceive the extent of disease activity differently. We aimed to assess the factors contributing to the variability in scoring of…
Abstract Number: 348 • 2013 ACR/ARHP Annual Meeting
Laboratory Abnormalities In Patients With Psoriatic Arthritis Receiving Apremilast, An Oral Phosphodiesterase 4 Inhibitor: Pooled Safety Analysis Of Three Phase 3, Randomized, Controlled Trials
Philip J. Mease¹, Arthur Kavanaugh², Adewale O. Adebajo³, Juan J. Gomez-Reino⁴, Jürgen Wollenhaupt⁵, Dafna D. Gladman⁶, Maurizio Cutolo⁷, Georg Schett⁸, Eric Lespessailles⁹, Kamal Shah¹⁰, ChiaChi Hu¹⁰, Randall M. Stevens¹⁰, Christopher J. Edwards¹¹ and Charles A. Birbara¹², ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²University of California San Diego, San Diego, CA, ³Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom, ⁴Hospital Clinico Universitario, Santiago, Spain, ⁵Schön Klinik Hamburg-Eilbek, Hamburg, Germany, ⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷University of Genova, Genova, Italy, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁹University of Orléans, Orléans, France, ¹⁰Celgene Corporation, Warren, NJ, ¹¹NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ¹²University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate inflammatory mediators. The PALACE 1, 2, and 3 trials compared the efficacy and…
Abstract Number: 349 • 2013 ACR/ARHP Annual Meeting
Serum CTX-I Predicts Systemic Bone Loss At The Hip Over 1 Year In Patients With Early Psoriatic Arthritis
Agnes Szentpetery¹, Mark Kilbane², Myra P. O'Keane², Muhammad Haroon³, Phil Gallagher⁴, Susan van der Kamp⁵, Malachi McMenna⁶ and Oliver FitzGerald³, ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Metabolism Laboratory, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ³Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁴Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁵DXA Unit, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁶Department of Endocrinology & Metabolic Bone Disease, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: There is a growing interest in bone and cartilage biomarkers that could be used predicting and assessing changes in structural damage in inflammatory arthritis.…
Abstract Number: 350 • 2013 ACR/ARHP Annual Meeting
Cortical Bone Density As Measured By Digital X-Ray Radiogrammetry Correlates with Radiographic Joint Damage In The Hands Within 1 Year In Psoriatic Arthritis
Agnes Szentpetery¹, Muhammad Haroon², Phil Gallagher³, Eric J. Heffernan⁴ and Oliver FitzGerald², ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ³Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁴Radiology, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Structural destruction in peripheral joints may occur over time in both PsA and RA. We previously reported that 47% of early PsA patients treated…
Abstract Number: 351 • 2013 ACR/ARHP Annual Meeting
Psoriatic Arthritis Mutilans: Clinical and Radiographic Definitions. A Systematic Review
Amir Haddad¹, Mansour Somaily², Sindhu R. Johnson³, Rouhi Fazelzad⁴, Amie T. Kron⁵, Cathy Chau⁶ and Vinod Chandran⁷, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Medicine, Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Medicine, Toronto Scleroderma Program, Toronto Western Hospital, Toronto General Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, ⁴Health Sciences Libraries - Toronto General Hospital, University Health Network, Toronto, ON, Canada, ⁵Medicine, Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, ⁶Medicine, Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic Arthritis Mutilans (PAM) is the most severe form of psoriatic arthritis. Research on PAM has been impeded by the lack of an accepted…
Abstract Number: 352 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Vaccination Against seasonal 2012 Influenza Virus Among Patients With Psoriatic Arthritis and Psoriasis
Arik Polackek¹, Yuri Korobko¹, Noa Madar-Balakirski¹, Uri Arad², David Levartovsky³, Ilana Kaufman⁴, Marina Anouk⁵, Irena Litinsky⁶, Ella Mendelson⁷, Daphna Paran⁸, Hagit Matz⁹, Dan Caspi¹⁰, Michal Mandelbaum¹¹ and Ori Elkayam¹², ¹Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel, ²Department of Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ³Rheumatology, Tel Aviv Medical Ctr, Tel Aviv, Israel, ⁴Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-aviv, Israel, ⁵Rheumatology, Tel Aviv Sourasky Medical Ctr, Tel-Aviv University, Tel Aviv, Israel, ⁶Department of Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel, ⁷Central Virology Laboratory, Sheba Medical Center, Ramat Gan, Israel, ⁸Rheumatology, Tel Aviv Sourasky Medical Ctr, Tel-Aviv university, Tel Aviv, Israel, ⁹Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ¹⁰Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ¹¹Central Virology Department, Sheba Medical Center, Tel Aviv, Israel, ¹²Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel- Aviv, Israel
Background/Purpose: Patients with psoriatic arthritis (PsA) and psoriasis (Pso) are considered to be immunosuppressed and are therefore recommended to receive vaccination against seasonal influenza. However,…
Abstract Number: 353 • 2013 ACR/ARHP Annual Meeting
Time Interval Between The Onset Of Psoriasis and The Onset Of Psoriatic Arthritis May Define Disease Subsets
Arane Thavaneswaran¹, Vinod Chandran² and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic Arthritis (PsA) is a heterogeneous disease with widely varying clinical features and outcomes. Phenotypic heterogeneity may reflect genetic heterogeneity. We aimed to investigate…
Abstract Number: 354 • 2013 ACR/ARHP Annual Meeting
Disease Burden Among Patients With Psoriatic Arthritis Who Have Experienced First Line Tumor Necrosis Factor Inhibitor Regimen Failure In The European Union
Siva Narayanan¹, Yao Lu², Richard Hutchings² and Amanda Baskett², ¹Evidence Generation, Value and Access Center, Ipsos Healthcare, Columbia, MD, ²Ipsos Healthcare, London, United Kingdom
Background/Purpose: Data on second line biologic patients who have experienced 1st line tumor necrosis factor inhibitor (TNF) failure and associated disease burden among patients (pts)…
Abstract Number: 355 • 2013 ACR/ARHP Annual Meeting
Response To Etanercept With Or Without Methotrexate Combination Therapy In Patients With Psoriatic Arthritis
Bernard Combe¹, Urs Kerkmann², Fiona Brock³ and Gaia Gallo², ¹Hôpital Lapeyronie-Service d'Immuno-rhumatologie, Montpellier, France, ²Pfizer Europe, Rome, Italy, ³Quanticate, Hitchin, Hertfordshire, United Kingdom
Background/Purpose: Randomized controlled trials in psoriatic arthrtitis (PsA) have allowed treatment with TNF inhibitors (TNFi) as monotherapy as well as co-medication with methotrexate (MTX), but…
Abstract Number: 356 • 2013 ACR/ARHP Annual Meeting
Outcomes Of Patients With Rheumatoid Arthritis and Comorbid Hyperlipidemia
L Rosenblatt¹, JR Curtis², G Yang¹ and T Hebden³, ¹Bristol-Myers Squibb, Plainsboro, NJ, ²University of Alabama at Birmingham, Birmingham, AL, ³Formerly of Bristol-Myers Squibb, Plainsboro, NJ
Background/Purpose: Patients (pts) with RA have an increased prevalence of cardiovascular disease (CVD). Whether due to comorbidity or related to RA medications, many pts with…
Abstract Number: 358 • 2013 ACR/ARHP Annual Meeting
Inflammatory Burden Predicts Carotid Plaque Progression and Subsequent Cardiovascular Events In Rheumatoid Arthritis: The 2-Year Prospective Cohort Study
Churl Hyun Im¹, Sang Hoon Kwon², Jeong Soo Eun¹, Na Ri Kim¹, Eon Jeong Nam¹ and Young Mo Kang³, ¹Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea, ²Internal medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea, ³Department of Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea
Background/Purpose: Rheumatoid arthritis (RA) patients have increased prevalence of carotid atherosclerosis, especially plaque formation, which has been associated with inflammatory burden in a previous study.…
Abstract Number: 359 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Treatment Increases Left Ventricular Ejection Fraction and Decreases Left Ventricular Mass Index In Rheumatoid Arthritis Patients Without Cardiac Symptoms : Assessment By Cardiac Magnetic Resonance Imaging At 3.0 Tesla
Hitomi Kobayashi^1,2, Isamu Yokoe³, Hiroshi Sato², Yasuyuki Kobayashi⁴, Kihei Yoneyama⁵, Masaharu Hirano⁶ and Masami Takei⁷, ¹Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Rheumatology, Itabashi Chuo Medical Center, Tokyo, Japan, ³Nihon University School of Medicine, Tokyo, Japan, ⁴Radiology, St.Marianna University School of Medicine, Kawasaki, Japan, ⁵Cardiology, St.Marianna University School of Medicine, Kawasaki, Japan, ⁶Cardiology, Tokyo Medical Colleage, Tokyo, Japan, ⁷Division of Hematology and Rheumatology, NIhon University School of Medicine, Tokyo, Japan
Background/Purpose: Left ventricular (LV) dysfunction in rheumatoid arthritis (RA) may result, at least in part, from inflammation that may be regional and global. Therefore, therapies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].